Pharma News News 20 December 2025

Mereo BioPharma stock crashes 88% after Phase 3 setrusumab miss sinks brittle-bone hopes

NEW YORK, December 29, 2025, 23:16 ET — Market closed Mereo BioPharma Group plc shares closed down 87.65% at $0.29 on Monday after the company disclosed late-stage data that failed to hit a key fracture-rate endpoint for setrusumab, its lead

30 December 2025

Pfizer stock holds near $25 as Wall Street waits for the next big catalyst

NEW YORK, December 28, 2025, 23:32 ET — Market closed. Pfizer Inc shares edged higher in the last U.S. session, closing Friday up 0.24% at $25.09. The stock traded between $24.92 and $25.11 on the day. Investing.com The modest move

29 December 2025

Financial Analysis · Investment · NYSE:PFE · Pharma News · Stock Market · Wall Street

Healthcare Stocks Outlook: Year-End Rotation, J&J’s Eczema Setback, and Managed-Care Scrutiny Shape the Setup Before Monday’s Open

NEW YORK, Dec. 27, 2025, 12:57 p.m. ET — Market closed (weekend) Healthcare stocks are heading into the final trading days of 2025 with a rare mix of “defensive” support and headline-driven volatility—exactly the combination that can matter most when

27 December 2025

Healthcare Stocks · Investment Strategies · Managed Care · Market Outlook · NYSE:JNJ · Pharma News

Merck (MRK) Stock Update: Weekend Wrap, Latest Headlines, Analyst Targets, and What to Watch Before Monday’s Open

NEW YORK, Dec. 27, 2025, 11:25 a.m. ET — Market closed (weekend) Merck & Co., Inc. (NYSE: MRK) heads into the final days of 2025 with investors weighing a steady holiday-week climb in the shares against a familiar set of

27 December 2025

Analyst Insights · Investment Tips · NYSE:MRK · Pharma News · Stock Market · Weekend Recap

Merck Stock (MRK) News and Forecasts: FDA Fast-Track Vouchers, TrumpRx Pricing Deal, and Cidara Acquisition in Focus Ahead of the Next Market Session

As of 2:34 a.m. ET in New York on Saturday, December 27, 2025, U.S. stock markets are closed for the weekend.Merck & Co., Inc. (NYSE: MRK) was last quoted around $106.78, up about 0.33% versus its prior close, based on

27 December 2025

FDA Updates · Investment Analysis · Mergers & Acquisitions · NYSE:MRK · Pharma News · Stock Market

Abivax (ABVX) Stock in Focus: Eli Lilly Takeover Chatter, Obefazimod Phase 3 Momentum, and What to Watch Before the Next U.S. Session

NEW YORK — Friday, December 26, 2025 (9:13 a.m. ET): U.S. stocks are heading into a thin, post‑Christmas trading day, with Wall Street set for a relatively muted open as investors digest a strong 2025 tape and look ahead to

26 December 2025

Clinical Trials · Investment Insights · Mergers & Acquisitions · NASDAQ:ABVX · NYSE:LLY · Pharma News · Stock Market

Zai Lab Limited Stock (NASDAQ: ZLAB) Today: Pre‑Market Watchlist After China’s COBENFY Approval, NRDL Renewals, and Fresh Pipeline Catalysts

New York — Friday, December 26, 2025, 9:08 a.m. ET. U.S. equities are not yet in the regular session as of this writing; the Nasdaq opens at 9:30 a.m. ET. Barron’s+1 That timing matters today because Zai Lab Limited (NASDAQ:

26 December 2025

Biotechnology · China Business · Investment Analysis · Pharma News · Stock Market

Panacea Biotec Share Price Surges on UNICEF Vaccine Contract Upgrade: News, Forecasts and Stock Analysis for 26 December 2025

Panacea Biotec Limited (NSE: PANACEABIO, BSE: 531349) became one of India’s standout movers on Friday, December 26, 2025, after the company disclosed a meaningful upgrade to its UNICEF vaccine supply award—an update that immediately lit up the stock tape even

26 December 2025

Company Analysis · Financial Forecasts · Investment Insights · Pharma News · Stock Market

AbbVie (ABBV) Stock News Today, Dec. 23, 2025: Beyond Botox Pipeline Push, Analyst Targets, and What to Watch Next

AbbVie Inc. (NYSE: ABBV) stock traded mostly steady to slightly higher on Tuesday, Dec. 23, 2025, as investors balanced a holiday-shortened trading week with a fresh burst of company-specific pipeline headlines and ongoing debate about U.S. drug-pricing policy. As of

23 December 2025

Company Updates · Healthcare Industry · Investment Analysis · Pharma News · Stock Market

Insmed (INSM) Stock News Today: Nasdaq‑100 Addition, Brensocatib Setback, and Updated Analyst Forecasts (Dec. 22, 2025)

Insmed Incorporated (NASDAQ: INSM) is ending 2025 with two headlines pulling the stock in opposite directions: fresh visibility from joining the Nasdaq‑100 Index and fresh volatility after a clinical disappointment for a key expansion effort. As of Monday, December 22,

22 December 2025

Analyst Forecasts · Biotech Investments · Nasdaq Updates · Pharma News · Stock Market

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $4.8B Cash Buyout at $14.50 Resets the Outlook (Dec. 20, 2025)

December 20, 2025 — Amicus Therapeutics, Inc. (NASDAQ: FOLD) has abruptly shifted from a “rare-disease growth story” to a merger-arbitrage stock after BioMarin Pharmaceutical announced a definitive, all-cash acquisition valued at roughly $4.8 billion. The headline number for shareholders: $14.50

20 December 2025

Biotech Stocks · Investment Strategies · Mergers & Acquisitions · NASDAQ:BMRN · NASDAQ:FOLD · Pharma News · Stock Market Analysis

GSK plc Stock News and Forecast (Dec. 20, 2025): TrumpRx Pricing Deal, Exdensur FDA Approval, Buybacks, and Analyst Targets

GSK plc (LSE: GSK; NYSE: GSK) heads into the weekend with a rare “everything-bagel” mix of catalysts: a new U.S. drug-pricing agreement tied to tariff relief, a fresh FDA approval that could reshape severe-asthma dosing schedules, expanding vaccine indications in

20 December 2025

FDA Approvals · Financial Forecasts · Investment Analysis · NYSE:GSK · Pharma News · Stock Market

Pharma News News 20 December 2025 - 30 December 2025